Drug intelligence / Profile preview

GC1140A

Development stage: Preclinical
Lead developer: GC Biopharma
Modality: Vaccines & Immunotherapeutics

Overview

GC1140A is a preclinical-stage vaccine candidate being developed by GC Biopharma (formerly Green Cross) for the prevention of Epstein-Barr virus (EBV) infection. EBV is a ubiquitous human herpesvirus associated with infectious mononucleosis and various malignancies, including Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma. GC1140A is part of GC Biopharma's infectious disease portfolio and aims to induce protective immunity against the virus, addressing a significant unmet medical need as there are currently no licensed vaccines for EBV.

Beyond the preview

Go deeper on GC1140A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC1140A.

Explore the full profile